• Large Print

S 2172

Title: Medical Innovation Act of 2017
Author: Sen. Elizabeth Warren (DEM-MA)

Department of Health and Human Services (HHS) for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research, including a drug for which a patent contains information that relates to, or is based upon, federally funded research.</p> <p>Each fiscal year, HHS must publish a list of manufacturers that make payments, each manufacturer's covered blockbuster drugs, and payment amounts.</p> <p>Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year.</p> ...

Introduced in Senate 11/29/2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. 11/29/2017

Bill Text
12/04/2017 - S 2172 (Introduced+in+Senate)
11/29/2017 - S 2172 (Introduced+in+Senate)

Add To Favorites In PHR

Author Details

    Sen. Elizabeth Warren (D-MA)
    () - U.S. Senate

    Visit their Website

    Contact Tips

    Capital Address:
    317 Hart Senate Office Building

    Washington, DC 20510
    Phone: (202) 224-4543

    District Address:
    2400 JFK Federal Building, 15 New Sudbury Street

    Boston, MA 02203
    Phone: (617) 565-3170


Driving Walking/Biking Public Transit  Get Directions